NKTR Trading Analysis - 11/06/2026 05:39 PM โ€” TRU-SENTIMENT

NKTR (Nektar Therapeutics) at $37.27. True Sentiment Bullish, delta 40-60 call 90% / put 10%, call $1,655,890 vs put $193,040. RSI 52.4.

TRU-SENTIMENT ยท DeltaNeutral

NKTR Trading Analysis - 11/06/2026 05:39 PM โ€” TRU-SENTIMENT

Options chain ยท Stock chart ยท Baseline chart

NKTR (Nektar Therapeutics) at $37.27. True Sentiment Bullish, delta 40-60 call 90% / put 10%, call $1,655,890 vs put $193,040. RSI 52.4.

Symbol
NKTR
Price
$37.27
Article bias (separate from True Sentiment)
neutral
Conviction
low
Published
2026-11-06 17:39:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options):

Options flow via True Sentiment (delta 40-60 only):

Call Volume: $1,655,890.00 (89.6%) Put Volume: $193,040.00 (10.4%) Total: $1,848,930.00

Sentiment: Bullish. Call contracts 1,412 vs put 139; call trades 34 vs put 26. Pure directional conviction strongly favors calls (89.6% dollar vol). This suggests near-term upside expectations despite bearish technicals. Divergence: Option spread engine reports "Divergence detected between technical indicators and options sentiment" with advice to wait for alignment.

Key Statistics: NKTR

$37.26 +2.93%
52-Week Range
$33.40 - $109.00
Market Cap
$1.27B
P/E (TTM)
4.50
PEG Ratio
N/A
Beta
1.34
Next Earnings
N/A
Avg Volume
$729,299
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)4.50
EPS (trailing 12 mo)$-2.87
Market cap$1.27B
Shares outstanding34.1M

Dividend

Dividend yield0.00%

Risk & range

Beta1.34
52-week low$33.40
52-week high$109.00
Historical volatility90.8%

Ownership & trading

Institutional ownership45.4%
Average daily volume0.8M sh

Reported figures; no analyst estimates.


๐Ÿ“ˆ Analysis

News Headlines & Context:

The following recent context items for Nektar Therapeutics (NKTR) are provided from general knowledge and are separate from the data-driven analysis below:

  • NKTR has been navigating a strategic pipeline shift, with recent focus on its immunology asset rezpegaldesleukin (REZPEG) and partner-dependent milestones.
  • In late 2026, the stock experienced a sharp repricing lower after a clinical or commercial update triggered heavy volume selling (observed thematically around early October in the embedded price data).
  • Biotech sector sentiment remained fragile amid rising rates and risk-off positioning, pressuring small-cap clinical-stage names.
  • No confirmed near-term FDA catalyst was widely telegraphed; investors were monitoring cash runway and partnership developments.
  • The embedded options data shows a bullish directional call lean despite weak technicals, possibly reflecting speculative positioning on a future catalyst.

Fundamental Analysis:

Based strictly on the provided FUNDAMENTALS data for NKTR:

MetricValue
Trailing P/E4.50
Trailing EPS-2.87
Market Cap1,272,168,180.00
Shares Outstanding34,143,000.00
Dividend Yield0.00
Beta1.34
52-Week High109.00
52-Week Low33.40
Institutional Ownership45.41%
Average Volume790,000.00
Historical Volatility90.78

Revenue growth, gross/operating/net margins, ROE, debt-to-equity, free cash flow, PEG ratio, forward P/E, and analyst target price are not available in the data (null). The negative EPS of -2.87 indicates the company is not profitable on a trailing basis. The low trailing P/E of 4.50 is distorted by negative earnings and is not a standard profitability-based valuation. Fundamentals show a clinical-stage profile with high volatility (90.78 historical) and moderate institutional holding (45.41%). This diverges from the bullish options sentiment but aligns with the bearish technical structure below.

Current Market Position:

Current price per indicators: $37.34. Recent daily action shows a decline from $60.40 (2026-09-28) to $37.34 (2026-11-06), with a 30-day range high of $62.40 and low of $35.61. Minute bars for 2026-11-05 to 2026-11-06 show opening at $38.36 (11-05) dropping to $36.20 close, then $36.58 open to $37.34 close on 11-06. Late session on 11-06 saw volume spikes: 51,513 at 15:50 and 49,656 at 15:55, with price dipping to $37.16 then recovering to $37.27. Intraday momentum is weak/choppy with no clear trend.

Support
$35.61
Resistance
$39.66
Last Close
$37.34

Technical Analysis:

Technical Indicators

RSI (14)
52.37
MACD
-3.70
MACD Signal
-2.96
MACD Hist
-0.74
SMA 5
37.29
SMA 20
37.73
SMA 50
51.95
BB Upper
39.66
BB Mid
37.73
BB Lower
35.80
ATR 14
1.66

SMA alignment: Price ($37.34) is below SMA 20 ($37.73) and far below SMA 50 ($51.95); SMA 5 ($37.29) is below SMA 20, confirming bearish structure. RSI at 52.37 is neutral, not oversold. MACD (-3.70) below signal (-2.96) with negative histogram (-0.74) shows bearish momentum. Bollinger mid $37.73, price inside lower half near $37.34; no squeeze signal. 30-day range: price at $37.34 is near lower third (low $35.61, high $62.40).

True Sentiment Analysis (Delta 40-60 Options):

Options flow via True Sentiment (delta 40-60 only):

Call Volume: $1,655,890.00 (89.6%) Put Volume: $193,040.00 (10.4%) Total: $1,848,930.00

Sentiment: Bullish. Call contracts 1,412 vs put 139; call trades 34 vs put 26. Pure directional conviction strongly favors calls (89.6% dollar vol). This suggests near-term upside expectations despite bearish technicals. Divergence: Option spread engine reports "Divergence detected between technical indicators and options sentiment" with advice to wait for alignment.

Key Price Levels (observational only):

30d Low
$35.61
BB Lower
$35.80
BB Upper
$39.66
SMA 20
$37.73
SMA 50
$51.95

Interactive charts load with JavaScript. This text is the crawlable summary.